

# Closing Gaps in Care in 2023: Medical Record Submissions

MVP Health Care<sup>®</sup> produces Gaps in Care (GIC) reports by Participating Provider for Commercial, Medicare, Medicaid, and HARP Members. For your convenience, GIC reports include all Members with at least one gap in care. Open gaps in care are labeled “Service Required,” closed gaps in care are labeled “Pass” in the Excel version of the report.

A gap in care can be closed by submitting the appropriate medical record documentation to MVP for the following measures:



## Adult Measures

- Cervical Cancer Screening (CCS)
- Chlamydia Screening in Women (CHL)
- Colorectal Cancer Screening (COL)
- Eye Exam for Patients with Diabetes (EED)
- Hemoglobin A1C Control for Patients with Diabetes (HBD)



## Submitting Medical Records to MVP

- Secure Fax: **888-219-5623**
- Secure Email:  
**[mvpgapclosures@mvphealthcare.com](mailto:mvpgapclosures@mvphealthcare.com)**  
*(Include the Gaps in Care Transmission Cover Sheet found in the Excel version of your GIC report when submitting medical records.)*



## Children's Measures

- Immunizations for Adolescents—  
Human Papillomavirus (IMA-HPV)
- Lead Screening in Children (LSC)



## Reminders

- Medical records submitted for other measures cannot be accepted
- Practices are invited to grant the MVP Quality team remote access to their EHR—our clinical review team will retrieve documentation required to close gaps in care. Contact Debra Carr at **585-885-2318** or **[hedisquality@mvphealthcare.com](mailto:hedisquality@mvphealthcare.com)** for more information



## Questions

Contact us at **[mvpgapclosures@mvphealthcare.com](mailto:mvpgapclosures@mvphealthcare.com)**.

# Closing Gaps in Care in 2023: Measure Review



## Adult Measures

### Measure Description

### Acceptable Medical Record Documentation

*(Continuity of Care documents cannot be accepted for any measure.)*

#### Cervical Cancer Screening (CCS)

Women 24–64 years of age who were screened for cervical cancer:

- Women ages 24–64 who had cervical cytology (Pap) testing during 2021–2023
- Women ages 30–64 who had cervical high-risk human papillomavirus (hrHPV) testing during 2019–2023 (including Pap/hrHPV co-testing)

- Cervical cytology (Pap) lab results during 2021–2023
- Cervical high-risk human papillomavirus (hrHPV) lab results during 2019–2023
- Visit note that includes the name of the screening test (Pap or HPV), date, and result
- Exclusions
  - Evidence of hysterectomy with no residual cervix (ex. complete, total, simple, vaginal hysterectomy) from procedure notes, visit notes, surgical history, problem lists any time through December 31, 2023  
*Reminder: notation of “hysterectomy” alone must include evidence of surgical absence of cervix such as documentation from a pelvic exam or procedure note.*
  - Confirmation of hospice, palliative care, or death in 2023

#### Chlamydia Screening in Women (CHL)

Women 16–24 years of age who were identified as sexually active and had one chlamydia test during 2023.

- Chlamydia lab results during 2023
- Visit note with date of chlamydia test and result in 2023
- Exclusions
  - Confirmation of hospice or death in 2023

## Adult Measures Continued

Measure Description	Acceptable Medical Record Documentation <i>(Continuity of Care documents cannot be accepted for any measure.)</i>
<b>Colorectal Cancer Screening (COL)</b>	
<p>Adults 45–75 years of age who had the following colorectal cancer screenings:</p> <ul style="list-style-type: none"> <li>• Colonoscopy during 2014–2023</li> <li>• Cologuard®/Stool DNA w/FIT test during 2021–2023</li> <li>• Fecal Occult blood test (FOBT) in 2023</li> <li>• CT Colonography (virtual) during 2019–2023</li> <li>• Flexible Sigmoidoscopy during 2019–2023</li> </ul>	<ul style="list-style-type: none"> <li>• Gastroenterology visit/procedure notes/operative reports</li> <li>• Lab/Pathology result reports</li> <li>• Visit note that includes the name of the colorectal screening test, date, and result</li> <li>• Exclusions               <ul style="list-style-type: none"> <li>◦ Evidence of colorectal cancer or total colectomy any time through December 31, 2023</li> <li>◦ Confirmation of hospice, palliative care, or death in 2023</li> </ul> </li> </ul>
<b>Eye Exam for Patients with Diabetes (EED)</b>	
<p>Adults 18–75 years of age with diabetes (type 1 or type 2) who had a retinal eye exam. Any of the following meet criteria:</p> <ul style="list-style-type: none"> <li>• Retinal or dilated eye exam by an optometrist or ophthalmologist during 2023</li> <li>• Retinal or dilated eye exam by an optometrist or ophthalmologist that is negative for retinopathy during 2022</li> <li>• Evidence of bilateral eye enucleation any time through December 31, 2023</li> </ul>	<ul style="list-style-type: none"> <li>• Note or letter from an ophthalmologist, optometrist, or PCP indicating an ophthalmoscopic exam was completed by an ophthalmologist or optometrist, the exam date, and the results</li> <li>• A chart or photograph indicating the date that fundus photography was performed and one of the following:               <ul style="list-style-type: none"> <li>◦ Evidence that an ophthalmologist or optometrist reviewed the results</li> <li>◦ Evidence results were read by a qualified reading center that operates under the direction of a medical director who is a retinal specialist</li> <li>◦ Evidence results were read by a system that provides artificial intelligence (AI) interpretation</li> </ul> </li> <li>• Exclusions               <ul style="list-style-type: none"> <li>◦ Confirmation of hospice, palliative care, or death in 2023</li> </ul> </li> </ul>
<b>Hemoglobin A1C Control for Patients with Diabetes (HBD)</b>	
<p>Adults 18–75 years of age with diabetes (type 1 or type 2) whose hemoglobin A1C (HbA1C) was at the following levels during 2023:</p> <ul style="list-style-type: none"> <li>• HbA1C Control &lt;8.0%</li> <li>• HbA1C Poor Control &gt;9.0%</li> </ul>	<ul style="list-style-type: none"> <li>• HbA1C lab result report during 2023</li> <li>• Visit note that includes the HbA1C test date and numeric result during 2023</li> <li>• Exclusions               <ul style="list-style-type: none"> <li>◦ Confirmation of hospice, palliative care, or death in 2023</li> </ul> </li> </ul>

# Children’s Measures

<b>Measure Description</b>	<b>Acceptable Medical Record Documentation</b> <i>(Continuity of Care documents cannot be accepted for any measure.)</i>
----------------------------	---

<b>Immunizations for Adolescents—Human Papillomavirus (IMA-HPV)</b>	
---	--

<p>Children 13 years of age who had the following:</p> <ul style="list-style-type: none"><li>• Two HPV immunizations on or between the ninth and 13th birthday at least 146 days apart or three HPV immunizations on or between the ninth and 13th birthday</li></ul>	<ul style="list-style-type: none"><li>• Immunization record that includes the antigen name and date administered</li><li>• Visit note with antigen name and date administered</li><li>• Anaphylaxis due to the HPV vaccine on or before 13th birthday</li><li>• Exclusions<ul style="list-style-type: none"><li>◦ Confirmation of hospice or death in 2023</li></ul></li></ul>
---	--

<b>Lead Screening in Children (LSC)</b>	
---	--

<p>Children who turn two years of age during 2023 who had at least one capillary or venous lead blood test by the second birthday.</p>	<ul style="list-style-type: none"><li>• Lead lab result report</li><li>• Visit note that includes the lead test date and result</li><li>• Exclusions<ul style="list-style-type: none"><li>◦ Confirmation of hospice or death during 2023</li></ul></li></ul>
--	--

The following Quality Measures should be monitored for your patients, however, medical records cannot be accepted to close a gap in care for these measures.

## Adult Measures

---

### **Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)**

Adults 18 years of age and older with schizophrenia or schizoaffective disorder who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

### **Blood Pressure Control for Patients with Diabetes (BPD)**

Adults 18–75 years of age with diabetes (type 1 or type 2) whose blood pressure was adequately controlled (<140/90) during 2023.

### **Breast Cancer Screening (BCS-E)**

Women 50–74 years of age who had a mammogram on or between October 1, 2021–December 3, 2023.

### **Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia (SMC)**

Adults 18–64 years of age with schizophrenia or schizoaffective disorder and cardiovascular disease who had an LDL-C test during 2023.

### **Diabetes Monitoring for People with Diabetes and Schizophrenia (SMD)**

Adults 18–64 years of age with schizophrenia or schizoaffective disorder and diabetes who had both an LDL-C test and an HbA1C test during 2023.

### **Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)**

Adults 18–64 years of age with schizophrenia, schizoaffective disorder or bipolar disorder who were dispensed an antipsychotic medication and had a glucose or HbA1C test during 2023.

### **Kidney Health Evaluation for Patients with Diabetes (KED)**

Adults 18–85 years of age with diabetes (type 1 or type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR) during 2023.

### **Osteoporosis Management in Women Who Had Fracture (OMW)**

Women 67–85 years of age who suffered a fracture and had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis in the six months after the fracture.

### **Statin Therapy for Patients with Cardiovascular Disease (SPC)**

Males 21–75 years of age and females 40–75 years of age who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:

- Received Statin Therapy in 2023—Members who were dispensed at least high-intensity or moderate-intensity statin medication
- Statin Adherence 80%—Members who remained on a high-intensity or moderate-intensity statin for at least 80% of the treatment period

### **Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)**

Adults 40 years of age and older with a new diagnosis of COPD or newly active COPD who received appropriate spirometry testing to confirm the diagnosis.

## Adult/Children's Measure

---

### Asthma Medication Ratio (AMR)

Children and adults five–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during 2023.

## Children's Measures

---

### Childhood Immunization Status (CIS)

Children two years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV); one measles, mumps and rubella (MMR); three haemophilus influenza type B (HIB); three hepatitis B (HepB); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); two influenza (Flu) vaccines by their second birthday.

Immunizations administered after the second birthday cannot be counted. Your GIC report will flag this date for you.

### Immunizations for Adolescents (IMA)

Children 13 years of age who had one dose of meningococcal vaccine on or between the 11th and 13th birthday, one Tdap vaccine on or between the 10th and 13th birthday.

### Follow-up Care for Children Prescribed ADHD Medication (ADD)

Children six–12 years of age newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed.

### Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

Children and adolescents one–17 years of age who had two or more antipsychotic prescriptions and received at least one blood glucose test or HbA1C and one LDL-C or cholesterol test during 2023.

### Well-Child Visits in the First 30 Months of Life (W30)\*

Well-child visits conducted by a PCP that includes a health history, physical developmental history, mental developmental history, physical exam, health education/anticipatory guidance. Goal is six or more well-child visits by 15-month birthday; two or more well-child visits between the child's 15-month birthday and 30-month birthday.

### Child and Adolescent Well-Care Visits (WCV)\*

Children three–21 years of age who had at least one comprehensive well-care visit conducted by a PCP or OB/GYN provider in 2023 that includes a health history, physical developmental history, mental developmental history, physical exam, health education/anticipatory guidance.

\*W30 and WCV are based on the Bright Futures/American Academy of Pediatrics (AAP) Recommendations for Preventive Pediatric Health Care. Visit [aap.org/en/practice-management/bright-futures](https://aap.org/en/practice-management/bright-futures) for more information.